Osimertinib is a third-generation, irreversible, oral EGFR-TKI that potently and selectively inhibits EGFR-TKI-sensitizing and EGFR p.Thr790Met variants with demonstrated efficacy in EGFR variant-positive NSCLC, including in patients with central nervous system (CNS) metastases [10,14–18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.